Cognitive Changes and Rehabilitation in People With Transient Ischemic Attack, Stroke, or Stroke Risk Factors
NCT ID: NCT01951612
Last Updated: 2016-07-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
40 participants
INTERVENTIONAL
2011-11-30
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
While there are many studies concerning rehabilitation of motor function and language in patients with large focal strokes, few studies have addressed attentional and executive functions. To our knowledge, there are no such studies on iWMD. In this study, patients will be randomized to a novel intervention for improving executive function and a control condition matched for therapist exposure. Patients will be assessed pre-intervention, post-intervention, and at long-term follow-up using a battery of behavioural and neuroimaging tasks. We predict that the novel intervention will be associated with improved executive function, as assessed behaviourally, and improved frontal network function, as assessed through neuroimaging markers.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Guided Training for People With Cognitive Impairment
NCT03225768
Computer-based Cognitive Rehabilitation Program for Healthy Older Adults, Older People With Mild Cognitive Impairment and Mild Dementia
NCT03430401
Neural Bases of Cognitive Rehabilitation for Brain Injury
NCT01120756
Post-stroke Cognitive Impairment and Dementia
NCT01339195
Psychoeducation for Transient Ischaemic Attack and Minor Stroke
NCT02550392
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Executive Function Training Program
Participants in this group will receive the novel intervention training.
Executive Function Training Program
Participants will take part in ten 2-hour sessions over 5 weeks.
Psychoeducational Training Program
Participants in this group will receive the control intervention training.
Psychoeducational Training Program
Participants will take part in ten 2-hour sessions over 5 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Executive Function Training Program
Participants will take part in ten 2-hour sessions over 5 weeks.
Psychoeducational Training Program
Participants will take part in ten 2-hour sessions over 5 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Fluent in English
* Able to provide informed consent to all procedures
* Sufficient motor and sensory functioning to complete all study components (with correction or assistance as required)
Exclusion Criteria
* Other psychiatric condition (other than mood, personality, or behaviour change following onset/diagnosis of white matter disease or related condition mentioned above)
* Other medical condition suspected to influence cognition
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sunnybrook Health Sciences Centre
OTHER
Baycrest
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Brian Levine
Senior Scientist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Brian Levine, PhD
Role: PRINCIPAL_INVESTIGATOR
Rotman Research Institute, Baycrest
Gary Turner, PhD
Role: PRINCIPAL_INVESTIGATOR
Sunnybrook Health Sciences Centre
Sandra Black, MD
Role: PRINCIPAL_INVESTIGATOR
Sunnybrook Health Sciences Centre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Baycrest
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
232-2009
Identifier Type: OTHER
Identifier Source: secondary_id
08-53
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.